Myocardial infarction

Stem cell transplantation for cardiac regeneration

Edmund Carvalho, Paul Verma, Kerry Hourigan, Rinti Banerjee

Research output: Contribution to journalArticleResearchpeer-review

Abstract

It is estimated that by 2030, almost 23.6 million people will perish from cardiovascular disease, according to the WHO. The review discusses advances in stem cell therapy for myocardial infarction, including cell sources, methods of differentiation, expansion selection and their route of delivery. Skeletal muscle cells, hematopoietic cells and mesenchymal stem cells (MSCs) and embryonic stem cells (ESCs)-derived cardiomyocytes have advanced to the clinical stage, while induced pluripotent cells (iPSCs) are yet to be considered clinically. Delivery of cells to the sites of injury and their subsequent retention is a major issue. The development of supportive scaffold matrices to facilitate stem cell retention and differentiation are analyzed. The review outlines clinical translation of conjugate stem cell-based cellular therapeutics post-myocardial infarction
Original languageEnglish
Pages (from-to)1025 - 1043
Number of pages19
JournalRegenerative Medicine
Volume10
Issue number8
DOIs
Publication statusPublished - 2015

Cite this

Carvalho, Edmund ; Verma, Paul ; Hourigan, Kerry ; Banerjee, Rinti. / Myocardial infarction : Stem cell transplantation for cardiac regeneration. In: Regenerative Medicine. 2015 ; Vol. 10, No. 8. pp. 1025 - 1043.
@article{92b72f6c1471421dba9c712b13e9b629,
title = "Myocardial infarction: Stem cell transplantation for cardiac regeneration",
abstract = "It is estimated that by 2030, almost 23.6 million people will perish from cardiovascular disease, according to the WHO. The review discusses advances in stem cell therapy for myocardial infarction, including cell sources, methods of differentiation, expansion selection and their route of delivery. Skeletal muscle cells, hematopoietic cells and mesenchymal stem cells (MSCs) and embryonic stem cells (ESCs)-derived cardiomyocytes have advanced to the clinical stage, while induced pluripotent cells (iPSCs) are yet to be considered clinically. Delivery of cells to the sites of injury and their subsequent retention is a major issue. The development of supportive scaffold matrices to facilitate stem cell retention and differentiation are analyzed. The review outlines clinical translation of conjugate stem cell-based cellular therapeutics post-myocardial infarction",
author = "Edmund Carvalho and Paul Verma and Kerry Hourigan and Rinti Banerjee",
year = "2015",
doi = "10.2217/rme.15.63",
language = "English",
volume = "10",
pages = "1025 -- 1043",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd",
number = "8",

}

Myocardial infarction : Stem cell transplantation for cardiac regeneration. / Carvalho, Edmund; Verma, Paul ; Hourigan, Kerry; Banerjee, Rinti.

In: Regenerative Medicine, Vol. 10, No. 8, 2015, p. 1025 - 1043.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Myocardial infarction

T2 - Stem cell transplantation for cardiac regeneration

AU - Carvalho, Edmund

AU - Verma, Paul

AU - Hourigan, Kerry

AU - Banerjee, Rinti

PY - 2015

Y1 - 2015

N2 - It is estimated that by 2030, almost 23.6 million people will perish from cardiovascular disease, according to the WHO. The review discusses advances in stem cell therapy for myocardial infarction, including cell sources, methods of differentiation, expansion selection and their route of delivery. Skeletal muscle cells, hematopoietic cells and mesenchymal stem cells (MSCs) and embryonic stem cells (ESCs)-derived cardiomyocytes have advanced to the clinical stage, while induced pluripotent cells (iPSCs) are yet to be considered clinically. Delivery of cells to the sites of injury and their subsequent retention is a major issue. The development of supportive scaffold matrices to facilitate stem cell retention and differentiation are analyzed. The review outlines clinical translation of conjugate stem cell-based cellular therapeutics post-myocardial infarction

AB - It is estimated that by 2030, almost 23.6 million people will perish from cardiovascular disease, according to the WHO. The review discusses advances in stem cell therapy for myocardial infarction, including cell sources, methods of differentiation, expansion selection and their route of delivery. Skeletal muscle cells, hematopoietic cells and mesenchymal stem cells (MSCs) and embryonic stem cells (ESCs)-derived cardiomyocytes have advanced to the clinical stage, while induced pluripotent cells (iPSCs) are yet to be considered clinically. Delivery of cells to the sites of injury and their subsequent retention is a major issue. The development of supportive scaffold matrices to facilitate stem cell retention and differentiation are analyzed. The review outlines clinical translation of conjugate stem cell-based cellular therapeutics post-myocardial infarction

U2 - 10.2217/rme.15.63

DO - 10.2217/rme.15.63

M3 - Article

VL - 10

SP - 1025

EP - 1043

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 8

ER -